La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Genexine Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	2.7yrs
Durata media del Consiglio di amministrazione	2.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Jul 12

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

Mar 14

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Mar 19

AMMINISTRATORE DELEGATO

Genexine non ha un CEO, o non abbiamo dati su di loro.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jungwon Woo	President & Director	2.7yrs	Nessun dato	0.012% ₩ 30.4m
Neil K. Warma	President & Director	2.3yrs	Nessun dato	Nessun dato
Young-Chul Sung	Founder & Chairman of the Scientific Advisory Board	no data	Nessun dato	5.88% ₩ 15.0b
Sung-June Hong	Executive VP	no data	Nessun dato	0.012% ₩ 30.8m
Jongsoo Lee	Senior Manager of IR & PR	no data	Nessun dato	Nessun dato
Hyun Jin Park	EVP of Corporate Development	2.7yrs	Nessun dato	Nessun dato
Jong Sup Park	Chief Medical Officer	5.5yrs	Nessun dato	Nessun dato
Jang Hee Lee	EVP of Operations	2.7yrs	Nessun dato	Nessun dato
Ki Yong Kim	SVP of Bio Research Institute	2.7yrs	Nessun dato	Nessun dato
Chul Jun Hyun	Auditor & Director	2.7yrs	Nessun dato	Nessun dato
Jaehyun Choi	Head of R&D	less than a year	Nessun dato	Nessun dato

2.7yrs

Durata media

Gestione esperta: Il team dirigenziale di A095700 è considerato esperto (durata media dell'incarico 2.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jungwon Woo	President & Director	2.7yrs	Nessun dato	0.012% ₩ 30.4m
Neil K. Warma	President & Director	2.3yrs	Nessun dato	Nessun dato
Young-Chul Sung	Founder & Chairman of the Scientific Advisory Board	2.6yrs	Nessun dato	5.88% ₩ 15.0b
Sung-June Hong	Executive VP	2.7yrs	Nessun dato	0.012% ₩ 30.8m
Chul Jun Hyun	Auditor & Director	2.7yrs	Nessun dato	Nessun dato
Young-Jin Kim	Chairman of BOD	2.7yrs	Nessun dato	Nessun dato
Keon Pai Jin	Non-Executive Director	2.7yrs	Nessun dato	Nessun dato
Mijung Ahn	Member of Scientific Advisory Board	2.7yrs	Nessun dato	Nessun dato
Peter Laivins	Director	2.7yrs	Nessun dato	Nessun dato
Hyeok Jong Lee	Director	2.7yrs	Nessun dato	Nessun dato
Heeseop Shin	Member of Scientific Advisory Board	2.7yrs	Nessun dato	Nessun dato
Munseok Gang	Member of Scientific Advisory Board	2.7yrs	Nessun dato	Nessun dato

2.7yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di A095700 non è considerato esperto (durata media del mandato 2.6 anni), il che suggerisce un nuovo consiglio.

Genexine Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

No independent directors

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

No independent directors

Recent updates

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

Full year 2023 earnings released: ₩1,652 loss per share (vs ₩1,715 loss in FY 2022)

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

New minor risk - Revenue size

New minor risk - Share price stability

Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority (BPOM)

Genexine Announces Positive Topline Results from the Multi-Center, Randomized, Open-Label, Active-Controlled Pivotal Phase 3 Study

Ajinomoto Co., Inc. (TSE:2802) agreed to acquire remaining 25% stake in Ajinomoto Genexine Co., Ltd from Genexine, Inc. (KOSDAQ:A095700) for KRW 19.3 billion.

Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for Its Promising DNA Vaccine for Advanced Cervical Cancer

Genexine, Inc. to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference

Genexine, Inc. has completed a Follow-on Equity Offering in the amount of KRW 82.044713 billion.

No independent directors

Genexine’s Announces that DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer

Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

Genexine Reports Encouraging Top-Line Results of the Phase 1B/2 Clinical Trial with GX-I7 (Efineptakin Alfa) in Refractory or Recurrent (R/R) Metastatic Triple Negative Breast Cancer

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

No independent directors

First quarter 2021 earnings released: EPS ₩861 (vs ₩628 loss in 1Q 2020)

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Genexine, Inc., Annual General Meeting, Mar 29, 2021

New 90-day low: ₩94,300

Turret Capital Management Signs A Definitive License Agreement with Genexine, Inc

New 90-day low: ₩103,600

Genexine, Inc. and NeoimmuneTech, Inc. Releases Data for Their Phase 1B/2 Study of Gx-I7/Nt-I7 and Keytruda® in Patients with Triple-Negative Breast Cancer

New 90-day low: ₩104,000

New 90-day low: ₩109,500

Genexine, Inc. announced that it has received KRW 3.29761 billion in funding from Handok, Inc.

New 90-day high - ₩132,000

New 90-day high - ₩130,600

AMMINISTRATORE DELEGATO

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media